Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities
Immune checkpoint inhibitors (ICIs) have become a cornerstone of treatment for many solid organ malignancies. Alongside increasing use, the occurrence of immune-related adverse events (irAEs) has also increased and remains a significant challenge when treating patients with ICI. The underlying patho...
Main Authors: | J. McKenzie, E. Sneath, A. Trinh, M. Nolan, L. Spain |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-03-01
|
Series: | Immuno-Oncology and Technology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590018824000017 |
Similar Items
-
Fatal Neutropenic Enterocolitis during Pegylated Interferon and Ribavirin Combination Therapy for Chronic Hepatitis C Virus Infection
Published: (2009-09-01) -
Myocarditis and pericarditis in young patients following Campylobacter jejuni enterocolitis infection: a systematic review of case studies
by: Katharine Sanicola, et al.
Published: (2024-11-01) -
Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study
by: Qing Liu, et al.
Published: (2024-08-01) -
Necrotizing enterocolitis report of 20 cases
by: M.H Daei-Parizi, et al.
Published: (1993-12-01) -
An Update on the Role of Extracellular Vesicles in the Pathogenesis of Necrotizing Enterocolitis and Inflammatory Bowel Diseases
by: Rafał Filip
Published: (2021-11-01)